2. Search Result
Search Result
Results for "

NHE3

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100325
    NHE3-IN-1

    		Na+/H+ Exchanger (NHE) Neurological Disease
    NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.
    <em>NHE3</em>-IN-1
  • HY-139313
    NHE3-IN-2

    		Na+/H+ Exchanger (NHE) Metabolic Disease
    NHE3-IN-2 is a Na +/H + exchanger-3 (NHE3) inhibitor ( patent WO2001079186A1, example 6-Chlor-4-phenyl-2-chinazolinyl-guanidin) .
    <em>NHE3</em>-IN-2
  • HY-101840A
    EIPA hydrochloride
    Maximum Cited Publications
    40 Publications Verification

    L593754 hydrochloride; MH 12-43 hydrochloride; Ethylisopropylamiloride hydrochloride

    		 TRP Channel Autophagy COX Prostaglandin Receptor Na+/H+ Exchanger (NHE) Inflammation/Immunology Cancer
    EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na +/H +-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma [3] .
    EIPA hydrochloride
  • HY-151360
    NHE3-IN-3

    		Sodium Channel Metabolic Disease
    NHE3-IN-3 (Compound 1) is a Na +/H + exchanger isoform 3 (NHE3) inhibitor with pIC50 of 6.2 and 6.6 against human and rat NHE3, respectively. NHE3-IN-3 shows high (98%) oral bioavailability in Sprague–Dawley rats .
    <em>NHE3</em>-IN-<em>3</em>
  • HY-132181
    Dimethylamiloride hydrochloride

    		Na+/H+ Exchanger (NHE) Inflammation/Immunology
    Dimethylamiloride hydrochloride is a Na +/H + exchanger NHE inhibitor with Ki values of 0.02, 0.25, and 14 μM for NHE1, NHE2, and NHE3, respectively. Dimethylamiloride hydrochloride can be used for pain research .
    Dimethylamiloride hydrochloride
  • HY-101840
    EIPA
    Maximum Cited Publications
    40 Publications Verification

    L593754; MH 12-43; Ethylisopropylamiloride

    		 TRP Channel Prostaglandin Receptor Autophagy COX Na+/H+ Exchanger (NHE) Inflammation/Immunology Cancer
    EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na +/H +-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma [3] .
    EIPA
  • HY-15991
    Tenapanor
    4 Publications Verification

    AZD1722; RDX5791

    		 Na+/H+ Exchanger (NHE) Metabolic Disease
    Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia .
    Tenapanor
  • HY-15991A
    Tenapanor hydrochloride
    4 Publications Verification

    AZD1722 hydrochloride; RDX5791 hydrochloride

    		 Na+/H+ Exchanger (NHE) Metabolic Disease
    Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia .
    Tenapanor hydrochloride
  • HY-18071
    BI-9627
    1 Publications Verification

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
    BI-9627
  • HY-18071A
    BI-9627 hydrochloride
    1 Publications Verification

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
    BI-9627 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: